Source: Annual Congress 2003 - Pulmonary circulation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. M. Maripov, A. S. Sarybaev, A. S. Sydykov, M. M. Mirrakhimov (Bishkek, Kyrgyzstan). Prediction of effects of calcium channel blockers (CCB) on hypoxic pulmonary hypertension (HPH) due to COPD. Eur Respir J 2003; 22: Suppl. 45, 1753

Member's Comments

No comment yet.

Related content which might interest you: Loss of response to calcium channel blockers after long-term follow up in idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 1354-1360 Year: 2009 Role of NO pathway, calcium and potassium channels in the peripheral pulmonary vascular tone in dogs Source: Eur Respir J 2001; 17: 20-26 Year: 2001 Effectiveness and safety of the antihypertensive treatment with ACE inhibitors (ACEi) and their combination with calcium antagonists (CA) of the patients with bronchial asthma (BA) and arterial hypertension (AH) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008 Calcium channels‘ blockers in therapy of COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 31s Year: 2006 Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats Source: Eur Respir J 2003; 21: 862-865 Year: 2003 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 SUR1/Kir6.2 potassium channel a new actor involved in pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade Source: Eur Respir J, 50 (6) 1701141; 10.1183/13993003.01141-2017 Year: 2017 Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Longterm treatment effects of pulmonary hypertantion (PH) in idiopathic pulmonary fibrosis (IPF) patients by endothelin receptor blockade (Bosentan) Source: Eur Respir J 2007; 30: Suppl. 51, 120s Year: 2007 Effects of amlodipine on pulmonary haemodynamics in pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 27s Year: 2002 Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Potassium channels in pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 1167-1177 Year: 2015 Inhalation of endothelin receptor blockers in pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD) Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007